



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



CYY292

Item No. 39831

CAS Registry No.: 2644673-04-9
Formal Name: N⁴-1H-indazol-6-yl-N²-[3-methoxy-4-(4-methyl-1-piperazinyl)phenyl]-5-methyl-2,4-pyrimidinediamine
MF: C₂₄H₂₈N₈O
FW: 444.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥3 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CYY292 is supplied as a solid. A stock solution may be made by dissolving the CYY292 in the solvent of choice, which should be purged with an inert gas. CYY292 is slightly soluble in ethanol and methanol.

Description

CYY292 is an inhibitor of PDGFR α , PDGFR β , FGFR1, -2, and -3, (IC₅₀s = 5.35, 4.6, 28, 28, and 78 nM, respectively).^{1,2} It is selective for these kinases over FGFR4 (IC₅₀ = >1,000 nM) but also inhibits c-Kit, VEGFR2, VEGFR1, and insulin-like growth factor 1 receptor (IGF-1R; IC₅₀s = 67, 33, 36, and 75 nM, respectively), as well as EGFR, Bruton's tyrosine kinase (BTK), cyclin-dependent kinase 4 (Cdk4)/cyclin D3, and MET (IC₅₀s = 128, 198, 214, and 396 nM, respectively).¹ CYY292 inhibits the proliferation of MG-63, U2OS, MNNG/HOS, and Saos-2 osteosarcoma cells (IC₅₀s = 0.84, 0.76, 1.36, and 0.72 μ M, respectively).² It inhibits the migration and invasion of U87MG and LN-229 glioblastoma cells when used at concentrations of 0.3 and 0.5 μ M.¹ CYY292 (30 mg/kg) decreases tumor volume and increases survival in a U87MG orthotopic mouse xenograft model.

References

1. Bi, Y., Zheng, R., Hu, J., *et al.* A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3 β / snail signaling axis. *Genes Dis.* **11(1)**, 479-494 (2023).
2. Chen, X., Liu, L., Liu, P., *et al.* Discovery of potent and orally bioavailable platelet-derived growth factor receptor (PDGFR) inhibitors for the treatment of osteosarcoma. *J. Med. Chem.* **65(7)**, 5374-5391 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM